宫颈癌EBRT与HDR腔内/组织间近距离治疗剂量合成及临床计划评估的适宜方法
该回顾性研究纳入22例接受体外放疗(EBRT)和高剂量率腔内近距离治疗(ICBT)的宫颈癌患者,比较全参数相加(FPA)法与三维形变剂量合成法。结果显示,基于形变配准的剂量合成所得危及器官D2cc和D0.1cc数值较低,但差异无统计学意义(P > .05),现行ABS推荐的FPA工作表可作为临床可接受的计划评估工具。
要点
- 形变配准剂量合成所得OAR D2cc和D0.1cc低于FPA法,但差异无统计学意义。
- 现行ABS推荐的FPA工作表可作为宫颈癌联合放疗计划评估的临床工具。
- 不同剂量累积方法间剂量体积直方图参数差异无统计学意义(P > .05)。
核心结论
- 与FPA法相比,基于形变配准的剂量合成显示较低的OAR D2cc和D0.1cc值,但差异无统计学意义。
- 当前ABS推荐的FPA工作表可作为临床可接受的计划评估工具。
研究设计与样本
- 回顾性评估22例接受EBRT和高剂量率ICBT的宫颈癌患者,所有患者使用分环和串联施源器,其中5例加用组织间插植针。
- 将第二次EBRT和ICBT计划CT形变配准至第三次ICBT分次的参考CT,使用Dice相似系数评估配准质量,剂量转换为2 Gy分次等效剂量后合成,比较8种剂量累积方法。
主要发现
- 全盆腔EBRT+ICBT的FPA法(旧ABS工作表,FPA_Eh + I_old)与EBRT推量+ICBT形变合成法(Def_E + B + I)相比,直肠、膀胱、乙状结肠和肠道D2cc差异分别为-2.19 ± 1.37 Gyα/β=3、-0.64 ± 1.13 Gyα/β=3、-2.06 ± 2.71 Gyα/β=3和-1.59 ± 0.89 Gyα/β=3。
- 新ABS工作表(FPA_Eh + B + I_abs)与Def_E + B + I法相比,直肠、膀胱、乙状结肠和肠道D2cc差异分别为1.21 ± 1.22 Gyα/β=3、1.93 ± 1.38 Gyα/β=3、0.72 ± 1.12 Gyα/β=3和1.19 ± 1.46 Gyα/β=3。
- Def_E + B + I与其他FPA方法间的剂量体积直方图参数差异无统计学意义(P > .05)。
关键数值与推荐
- 研究评估了8种剂量累积方法,主要比较D2cc和D0.1cc危及器官剂量参数。
- 形变配准质量采用Dice相似系数评估。
- 剂量转换为2 Gy分次等效剂量(α/β=3)后进行合成与比较。
临床怎么用
- 临床可采用现行ABS推荐的FPA工作表进行宫颈癌EBRT联合ICBT的计划评估。
- 形变配准剂量合成可作为更精确的评估手段,但与本研究中FPA法的差异未达统计学意义。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study assessed the appropriateness of full parameter addition (FPA) methods with respect to the 3-dimensional deformable dose composite method for evaluating combined external beam radiation therapy (EBRT) and intracavitary brachytherapy (ICBT). METHODS AND MATERIALS: A total of 22 patients who received EBRT and high-dose-rate ICBT were retrospectively evaluated. Split-ring and tandem applicators were used for all patients. Additional interstitial needles were used for 5 patients to supplement the implant. Deformable image registrations were performed to deform the secondary EBRT and ICBT planning computed tomography (CT) images onto the reference CT from the third fraction of ICBT. The Dice similarity coefficient was used to evaluate the quality of deformable registration. Doses were transferred to the reference CT, scaled to the equivalent dose in 2-Gy fractions and combined to create the dose composite. Eight dose-accumulation methods were evaluated and compared. D2cc and D0.1cc for organs at risk were investigated. RESULTS: The differences in D2cc for rectum, bladder, sigmoid, and bowel between the FPA method for whole-pelvis EBRT and ICBT, calculated using an old American Brachytherapy Society worksheet (FPA_Eh + I_old) and deformable composite for EBRT with boosts and ICBT (Def_E + B + I) were -2.19 ± 1.37 Gyα/β = 3, -0.64 ± 1.13 Gyα/β = 3, -2.06 ± 2.71 Gyα/β = 3, and -1.59 ± 0.89 Gyα/β = 3, respectively. The differences in D2cc for rectum, bladder, sigmoid, and bowel between the new ABS worksheet (FPA_Eh + B + I_abs) and the Def_E + B + I method were 1.21 ± 1.22 Gy α/β = 3, 1.93 ± 1.38 Gyα/β = 3, 0.72 ± 1.12 Gyα/β = 3, and 1.19 ± 1.46 Gyα/β = 3, respectively. Differences in dose-volume histogram parameter values among Def_E + B + I and other FPA methods were not statistically significant (P > .05). CONCLUSIONS: Compared with the FPA-based method, deformable registration-based dose composites demonstrated lower OAR D2cc and D0.1cc values; however, the differences were not statistically significant. The current ABS-recommended FPA-based sheet can serve as an acceptable plan evaluation tool for clinical purposes.
引用
- Xu Z, Traughber BJ, Fredman E, et al. Appropriate Methodology for EBRT and HDR Intracavitary/Interstitial Brachytherapy Dose Composite and Clinical Plan Evaluation for Patients With Cervical Cancer. Pract Radiat Oncol. 2019. PMID: 31238167. doi:10.1016/j.prro.2019.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。